Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 23
1.
Cir. Esp. (Ed. impr.) ; 101(11): 778-786, Noviembre 2023. tab
Article En | IBECS | ID: ibc-227086

Objectives In recent years, video-assisted thoracoscopic lung resections (VATS) have been associated with lower morbidity than open surgery. The aim of our study is to compare postoperative morbidity among patients from the national database of the Spanish Group of Video-Assisted Thoracic Surgery (GE-VATS) after open and video-assisted anatomic lung resections using a propensity score analysis.MethodsFrom December 2016 to March 2018, a total of 3533 patients underwent anatomical lung resection at 33 centers. Pneumonectomies and extended resections were excluded. A propensity score analysis was performed to compare the morbidity of the thoracotomy group (TG) vs the VATS group (VATSG). Treatment and intention-to-treat (ITT) analyses were conducted.ResultsIn total, 2981 patients were finally included in the study: 1092 (37%) in the TG and 1889 (63%) in the VATSG for the treatment analysis; and 816 (27.4%) in the TG and 2165 patients (72.6%) in the VATSG for the ITT analysis. After propensity score matching, in the treatment analysis, the VATSG was significantly associated with fewer overall complications than the TG OR 0.680 [95%CI 0.616, 0.750]), fewer respiratory (OR 0.571 [0.529, 0.616]) cardiovascular (OR 0.529 [0.478, 0.609]) and surgical (OR 0.875 [0.802, 0.955]) complications, lower readmission rate (OR 0.669 [0.578, 0.775]) and a reduction of hospital length of stay (−1.741 ([−2.073, −1.410]). Intention-to-treat analysis showed only statistically significant differences in overall complications (OR 0.76 [0.54–0.99]) in favor of the VATSG.ConclusionIn this multicenter population, VATS anatomical lung resections have been associated with lower morbidity than those performed by thoracotomy. However, when an intention-to-treat analysis was performed, the benefits of the VATS approach were less prominent. (AU)


Introducción El objetivo de nuestro estudio es comparar la morbilidad postoperatoria entre los pacientes de la base de datos nacional del Grupo Español de Cirugia Torácica Videoasistida (GE-VATS) después de resecciones pulmonares anatómicas abiertas y videoasistidas mediante un análisis de emparejamiento por índice de propensión.MétodosDesde Diciembre de 2016 hasta Marzo de 2018, un total 3533 pacientes fueron intervenidos de resección pulmonar anatómica en 33 centros. Se excluyeron las neumonectomías y las resecciones extendidas. Se realizó un análisis de índice de propensión para comparar la morbilidad de cirugía abierta (TG) frente a VATS (VATSG). Se realizó un análisis por tratamiento y por intención de tratar (ITT).ResultadosEn el estudio se incluyeron finalmente 2981 pacientes: 1092 (37%) en TG y 1889 (63%) en VATSG. En el análisis por tratamiento, la VATS se asoció significativamente con menor tasa de complicaciones que la cirugía abierta (OR 0.680 [95%CI 0.616, 0.750]), de complicaciones respiratorias (OR 0.571 [0.529, 0.616]), cardiovasculares (OR 0.529 [0.478, 0.609]) y quirúrgicas (OR 0.875 [0.802, 0.955]), menor tasa de reingresos (OR 0.669 [0.578, 0.775]) y menor estancia (−1.741 ([−2.073, −1.410]). En el de intención de tratar, se observaron diferencias estadísticamente significativas a favor de la VATS solo en las complicaciones en general (OR 0.76 [0.54–0.99]).ConclusionesEn esta población multicéntrica, las lobectomías y segmentectomias anatómicas por VATS se han asociado con menor tasa de complicaciones que las realizadas por toracotomía. Sin embargo, en el análisis por intención de tratar, los beneficios de la VATS no fueron tan evidentes. (AU)


Humans , Morbidity , Thoracic Surgery, Video-Assisted , Thoracotomy
2.
Cir Esp (Engl Ed) ; 101(11): 778-786, 2023 Nov.
Article En | MEDLINE | ID: mdl-37422151

OBJECTIVES: In recent years, video-assisted thoracoscopic lung resections (VATS) have been associated with lower morbidity than open surgery. The aim of our study is to compare postoperative morbidity among patients from the national database of the Spanish Group of Video-Assisted Thoracic Surgery (GE-VATS) after open and video-assisted anatomic lung resections using a propensity score analysis. METHODS: From December 2016 to March 2018, a total of 3533 patients underwent anatomical lung resection at 33 centers. Pneumonectomies and extended resections were excluded. A propensity score analysis was performed to compare the morbidity of the thoracotomy group (TG) vs the VATS group (VATSG). Treatment and intention-to-treat (ITT) analyses were conducted. RESULTS: In total, 2981 patients were finally included in the study: 1092 (37%) in the TG and 1889 (63%) in the VATSG for the treatment analysis; and 816 (27.4%) in the TG and 2165 patients (72.6%) in the VATSG for the ITT analysis. After propensity score matching, in the treatment analysis, the VATSG was significantly associated with fewer overall complications than the TG OR 0.680 [95%CI 0.616, 0.750]), fewer respiratory (OR 0.571 [0.529, 0.616]) cardiovascular (OR 0.529 [0.478, 0.609]) and surgical (OR 0.875 [0.802, 0.955]) complications, lower readmission rate (OR 0.669 [0.578, 0.775]) and a reduction of hospital length of stay (-1.741 ([-2.073, -1.410]). Intention-to-treat analysis showed only statistically significant differences in overall complications (OR 0.76 [0.54-0.99]) in favor of the VATSG. CONCLUSION: In this multicenter population, VATS anatomical lung resections have been associated with lower morbidity than those performed by thoracotomy. However, when an intention-to-treat analysis was performed, the benefits of the VATS approach were less prominent.


Lung Neoplasms , Humans , Lung Neoplasms/surgery , Thoracic Surgery, Video-Assisted/adverse effects , Thoracotomy , Intention to Treat Analysis , Morbidity , Lung/surgery
3.
Cir. Esp. (Ed. impr.) ; 101(1): 43-50, en. 2023. ilus, tab, graf
Article Es | IBECS | ID: ibc-EMG-426

Introducción: El objetivo de este estudio es crear un modelo predictivo de estancia postoperatoria prolongada (EPP) en pacientes sometidos a resección pulmonar anatómica, validarlo en una serie externa y evaluar la influencia de la EPP en el reingreso y la mortalidad a 90 días. Métodos: Se incluyeron todos los pacientes registrados en la base de datos del GEVATS dados de alta tras la intervención. Definimos la EPP como la permanencia postoperatoria en días por encima del percentil 75 de estancia de todos los pacientes de la serie. Se realizó un análisis univariable y multivariable mediante regresión logística y el modelo fue validado en una cohorte externa. Se analizó la posible asociación entre la EPP y el reingreso y la mortalidad a 90 días. Resultados: Se incluyeron en el estudio 3473 pacientes. La mediana de estancia postoperatoria fue de 5 días (RIQ:4-7). Ochocientos quince pacientes tuvieron una EPP (≥8 días), de los que el 79,9% presentaron complicaciones postoperatorias. El modelo final incluyó como variables: edad, IMC, sexo varón, VEF1%ppo, DLCO%ppo y toracotomía; el AUC en la serie de derivación fue de 0,684 (IC95%: 0,661-0,706) y en la de validación de 0,73 (IC95%: 0,681-0,78). Se encontró una asociación significativa entre la EPP y el reingreso (p<0,000) y la mortalidad a 90 días (p<0,000). Conclusiones: Las variables edad, IMC, sexo varón, VEF1%ppo, DLCO%ppo y toracotomía afectan a la EPP. La EPP se asocia con un incremento del riesgo de reingreso y mortalidad a 90 días. El 20% de las EPP no se relacionan con la ocurrencia de complicaciones postoperatorias. (AU)


Introduction: The objective of this study is to create a predictive model of prolonged postoperative length of stay (PLOS) in patients undergoing anatomic lung resection, to validate it in an external series and to evaluate the influence of PLOS on readmission and 90-day mortality. Methods: All patients registered in the GEVATS database discharged after the intervention were included. We define PLOS as the postoperative stay in days above the 75th percentile of stay for all patients in the series. A univariate and multivariate analysis was performed using logistic regression and the model was validated in an external cohort. The possible association between PPE and readmission and mortality at 90 days was analyzed. Results: 3473 patients were included in the study. The median postoperative stay was 5 days (IQR: 4–7). 815 patients had PLOS (≥8 days), of which 79.9% had postoperative complications. The final model included as variables: age, BMI, male sex, ppoFEV1%, ppoDLCO% and thoracotomy; the AUC in the referral series was 0.684 (95% CI: 0.661–0.706) and in the validation series was 0.73 (95% CI: 0.681–0.78). A significant association was found between PLOS and readmission (p<.000) and 90-day mortality (p<.000). Conclusions: The variables age, BMI, male sex, ppoFEV1%, ppoDLCO% and thoracotomy affect PLOS. PLOS is associated with an increased risk of readmission and 90-day mortality. 20% of PLOS are not related to the occurrence of postoperative complications. (AU)


Humans , Male , Female , Middle Aged , Aged , Hospitalization , Thoracic Surgery, Video-Assisted , Pneumonectomy , Spain , Patient Readmission
4.
Cir. Esp. (Ed. impr.) ; 101(1): 43-50, en. 2023. ilus, tab, graf
Article Es | IBECS | ID: ibc-226686

Introducción: El objetivo de este estudio es crear un modelo predictivo de estancia postoperatoria prolongada (EPP) en pacientes sometidos a resección pulmonar anatómica, validarlo en una serie externa y evaluar la influencia de la EPP en el reingreso y la mortalidad a 90 días. Métodos: Se incluyeron todos los pacientes registrados en la base de datos del GEVATS dados de alta tras la intervención. Definimos la EPP como la permanencia postoperatoria en días por encima del percentil 75 de estancia de todos los pacientes de la serie. Se realizó un análisis univariable y multivariable mediante regresión logística y el modelo fue validado en una cohorte externa. Se analizó la posible asociación entre la EPP y el reingreso y la mortalidad a 90 días. Resultados: Se incluyeron en el estudio 3473 pacientes. La mediana de estancia postoperatoria fue de 5 días (RIQ:4-7). Ochocientos quince pacientes tuvieron una EPP (≥8 días), de los que el 79,9% presentaron complicaciones postoperatorias. El modelo final incluyó como variables: edad, IMC, sexo varón, VEF1%ppo, DLCO%ppo y toracotomía; el AUC en la serie de derivación fue de 0,684 (IC95%: 0,661-0,706) y en la de validación de 0,73 (IC95%: 0,681-0,78). Se encontró una asociación significativa entre la EPP y el reingreso (p<0,000) y la mortalidad a 90 días (p<0,000). Conclusiones: Las variables edad, IMC, sexo varón, VEF1%ppo, DLCO%ppo y toracotomía afectan a la EPP. La EPP se asocia con un incremento del riesgo de reingreso y mortalidad a 90 días. El 20% de las EPP no se relacionan con la ocurrencia de complicaciones postoperatorias. (AU)


Introduction: The objective of this study is to create a predictive model of prolonged postoperative length of stay (PLOS) in patients undergoing anatomic lung resection, to validate it in an external series and to evaluate the influence of PLOS on readmission and 90-day mortality. Methods: All patients registered in the GEVATS database discharged after the intervention were included. We define PLOS as the postoperative stay in days above the 75th percentile of stay for all patients in the series. A univariate and multivariate analysis was performed using logistic regression and the model was validated in an external cohort. The possible association between PPE and readmission and mortality at 90 days was analyzed. Results: 3473 patients were included in the study. The median postoperative stay was 5 days (IQR: 4–7). 815 patients had PLOS (≥8 days), of which 79.9% had postoperative complications. The final model included as variables: age, BMI, male sex, ppoFEV1%, ppoDLCO% and thoracotomy; the AUC in the referral series was 0.684 (95% CI: 0.661–0.706) and in the validation series was 0.73 (95% CI: 0.681–0.78). A significant association was found between PLOS and readmission (p<.000) and 90-day mortality (p<.000). Conclusions: The variables age, BMI, male sex, ppoFEV1%, ppoDLCO% and thoracotomy affect PLOS. PLOS is associated with an increased risk of readmission and 90-day mortality. 20% of PLOS are not related to the occurrence of postoperative complications. (AU)


Humans , Male , Female , Middle Aged , Aged , Hospitalization , Thoracic Surgery, Video-Assisted , Pneumonectomy , Spain
5.
Cir Esp (Engl Ed) ; 101(1): 43-50, 2023 Jan.
Article En | MEDLINE | ID: mdl-35787477

INTRODUCTION: The objective of this study is to create a predictive model of prolonged postoperative length of stay (PLOS) in patients undergoing anatomic lung resection, to validate it in an external series and to evaluate the influence of PLOS on readmission and 90-day mortality. METHODS: All patients registered in the GEVATS database discharged after the intervention were included. We define PLOS as the postoperative stay in days above the 75th percentile of stay for all patients in the series. A univariate and multivariate analysis was performed using logistic regression and the model was validated in an external cohort. The possible association between PLOS and readmission and mortality at 90 days was analyzed. RESULTS: 3473 patients were included in the study. The median postoperative stay was 5 days (IQR: 4-7). 815 patients had PLOS (≥8 days), of which 79.9% had postoperative complications. The final model included as variables: age, BMI, male sex, ppoFEV1%, ppoDLCO% and thoracotomy; the AUC in the referral series was 0.684 (95% CI: 0.661-0.706) and in the validation series was 0.73 (95% CI: 0.681-0.78). A significant association was found between PLOS and readmission (p < .000) and 90-day mortality (p < .000). CONCLUSIONS: The variables age, BMI, male sex, ppoFEV1%, ppoDLCO% and thoracotomy affect PLOS. PLOS is associated with an increased risk of readmission and 90-day mortality. 20% of PLOS are not related to the occurrence of postoperative complications.


Postoperative Complications , Humans , Male , Risk Factors , Length of Stay , Retrospective Studies , Logistic Models , Postoperative Complications/etiology
6.
Cir Esp (Engl Ed) ; 100(6): 345-351, 2022 Jun.
Article En | MEDLINE | ID: mdl-35643356

INTRODUCTION: To analyze the predictors of pCR in NSCLC patients who underwent anatomical lung resection after induction therapy and to evaluate the postoperative results of these patients. METHODS: All patients prospectively registered in the database of the GE-VATS working group undergone anatomic lung resection by NSCLC after induction treatment and recruited between 12/20/2016 and 3/20/2018 were included in the study. The population was divided into two groups: patients who obtained a complete pathological response after induction (pCR) and patients who did not obtain a complete pathological response after induction (non-pCR). A multivariate analysis was performed using a binary logistic regression to determine the predictors of pCR and the postoperative results of patients were analyzed. RESULTS: Of the 241 patients analyzed, 36 patients (14.9%) achieved pCR. Predictive factors for pCR are male sex (OR: 2.814, 95% CI: 1.015-7.806), histology of squamous carcinoma (OR: 3.065, 95% CI: 1.233-7.619) or other than adenocarcinoma (OR: 5.788, 95% CI: 1.878-17.733) and induction therapy that includes radiation therapy (OR: 4.096, 95% CI: 1.785-9.401) and targeted therapies (OR: 7.625, 95% CI: 2.147-27.077). Prevalence of postoperative pulmonary complications was higher in patients treated with neoadjuvant chemo-radiotherapy (p = 0.032). CONCLUSIONS: Male sex, histology of squamous carcinoma or other than ADC, and induction therapy that includes radiotherapy or targeted therapy are positive predictors for obtaining pCR. Induction chemo-radiotherapy is associated with a higher risk of postoperative pulmonary complications.


Carcinoma, Non-Small-Cell Lung , Carcinoma, Squamous Cell , Lung Neoplasms , Carcinoma, Non-Small-Cell Lung/complications , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Carcinoma, Squamous Cell/surgery , Female , Humans , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Pneumonectomy/adverse effects , Pneumonectomy/methods , Postoperative Complications/etiology , Thoracic Surgery, Video-Assisted/methods
7.
Transl Lung Cancer Res ; 10(4): 1761-1772, 2021 Apr.
Article En | MEDLINE | ID: mdl-34012791

BACKGROUND: The Spanish Customized Adjuvant Therapy (SCAT) trial assessed the role of individualized adjuvant therapy in clinical N0 incidental pN1 and/or N2 non-small cell lung cancer (NSCLC) completely resected. We assessed surgical topics with an in-depth analysis of quality of lymphadenectomy based on International Association for the Study of Lung Cancer (IASLC) recommendations. METHODS: Patients with information about lymphadenectomy available were included (N=451). Prospectively collected data about tumor, type of resection, and postoperative morbidity and quality of lymph node dissection (LND) were retrospectively evaluated. Role of lymph node assessment on survival was analyzed using Kaplan-Meier curves, using regression models to identify prognostic factors. RESULTS: In 33.7%, 17.7% and 49.9% of cases, regions 7, 10 and 11 respectively were not assessed. In 21.1% of patients, less than three lymph node regions were biopsied, while in 19.6% of patients less than six lymph nodes were assessed. In 53,4% of patients only one N1 region was evaluated. From patients with positive N2, 8.9% had no N1 regions biopsied. Twenty-nine percent of patients with at least one N2 lymph node resected shown the highest region involved. Thirty-day postoperative mortality was unknown. Five-year overall survival (OS) was 61.7% (95% CI: 55.4-67.4%), 51.5% (95% CI: 39.2-62.4%) and 42.3% (95% CI: 32.1-52.2%) for patients with N1, N2 and N1+N2 disease, respectively (P<0.01). Both number of lymph nodes resected and number of lymph nodes involved by tumor were significantly related to prognosis. CONCLUSIONS: IASLC recommendations for surgical resections were not followed in a high proportion of surgical procedures. Hilar and mediastinal lymph node assessment and involvement showed to impact prognosis. Surgical issues such as postoperative mortality could not be evaluated owing to trial design.

8.
Cir Esp (Engl Ed) ; 2021 Feb 24.
Article En, Es | MEDLINE | ID: mdl-33640140

INTRODUCTION: To analyze the predictors of pathological complete response (pCR) in not small cells lung carcinoma (NSCLC) patients who underwent anatomical lung resection after induction therapy and to evaluate the postoperative results of these patients. METHODS: All patients prospectively registered in the database of the GE-VATS working group undergone anatomic lung resection by NSCLC after induction treatment and recruited between December 20th 2016, and March 20th 2018, were included in the study. The population was divided into two groups: patients who obtained a complete pathological response after induction (pCR) and patients who did not obtain a complete pathological response after induction (non-pCR). A multivariate analysis was performed using a binary logistic regression to determine the predictors of pCR and the postoperative results of patients were analyzed. RESULTS: Of the 241 patients analyzed, 36 patients (14.9%) achieved pCR. Predictive factors for pCR are male sex (OR 2.814, 95% CI 1.015-7.806), histology of squamous carcinoma (OR 3.065, 95% CI 1.233-7.619) or other than adenocarcinoma (ADC) (OR 5.788, 95% CI 1.878-17.733) and induction therapy that includes radiation therapy (OR 4.096, 95% CI 1.785-9.401) and targeted therapies (OR 7.625, 95% CI 2.147-27.077). Prevalence of postoperative pulmonary complications was higher in patients treated with neoadjuvant chemo-radiotherapy (p = 0.032). CONCLUSIONS: Male sex, histology of squamous carcinoma or other than ADC, and induction therapy that includes radiotherapy or targeted therapy are positive predictors for obtaining pCR. Induction chemo-radiotherapy is associated with a higher risk of postoperative pulmonary complications.

11.
Arch. bronconeumol. (Ed. impr.) ; 52(7): 378-388, jul. 2016. tab, ilus
Article Es | IBECS | ID: ibc-154238

La Sociedad Española de Neumología y Cirugía Torácica (SEPAR), a través de las áreas de Cirugía Torácica y de Oncología Torácica, ha promovido la realización de un manual de recomendaciones para el diagnóstico y el tratamiento del cáncer de pulmón de células no pequeñas. Las elevadas incidencia y mortalidad de esta patología hacen necesaria una constante actualización de las mejores evidencias científicas para su consulta por parte de los profesionales de la salud. Para su confección se ha contado con un amplio grupo de profesionales de distintas especialidades que han elaborado una revisión integral, que se ha concretado en 4 apartados principales. En el primero se ha estudiado la prevención y el cribado de la enfermedad, incluyendo los factores de riesgo, el papel de la deshabituación tabáquica y el diagnóstico precoz mediante programas de cribado. En un segundo apartado se ha analizado la presentación clínica, los estudios de imagen y el riesgo quirúrgico, incluyendo el cardiológico y la evaluación funcional respiratoria. Un tercero trata sobre los estudios de confirmación cito-histológica y de estadificación, con un análisis de las clasificaciones TNM e histológica, métodos no invasivos y mínimamente invasivos, así como las técnicas quirúrgicas para el diagnóstico y estadificación. En un cuarto y último capítulo se han abordado aspectos del tratamiento, como el papel de las técnicas quirúrgicas, la quimioterapia, la radioterapia, el abordaje multidisciplinar por estadios y otros tratamientos dirigidos frente a dianas específicas, terminando con recomendaciones acerca del seguimiento del cáncer de pulmón y los tratamientos paliativos quirúrgicos y endoscópicos en estadios avanzados


The Thoracic Surgery and Thoracic Oncology groups of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) have backed the publication of a handbook on recommendations for the diagnosis and treatment of non-small cell lung cancer. Due to the high incidence and mortality of this disease, the best scientific evidence must be constantly updated and made available for consultation by healthcare professionals. To draw up these recommendations, we called on a wide-ranging group of experts from the different specialties, who have prepared a comprehensive review, divided into 4 main sections. The first addresses disease prevention and screening, including risk factors, the role of smoking cessation, and screening programs for early diagnosis. The second section analyzes clinical presentation, imaging studies, and surgical risk, including cardiological risk and the evaluation of respiratory function. The third section addresses cytohistological confirmation and staging studies, and scrutinizes the TNM and histological classifications, non-invasive and minimally invasive sampling methods, and surgical techniques for diagnosis and staging. The fourth and final section looks at different therapeutic aspects, such as the role of surgery, chemotherapy, radiation therapy, a multidisciplinary approach according to disease stage, and other specifically targeted treatments, concluding with recommendations on the follow-up of lung cancer patients and surgical and endoscopic palliative interventions in advanced stages


Humans , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/therapy , Practice Patterns, Physicians' , Evidence-Based Practice , Smoking Cessation
12.
Arch Bronconeumol ; 52(7): 378-88, 2016 Jul.
Article En, Es | MEDLINE | ID: mdl-27237592

The Thoracic Surgery and Thoracic Oncology groups of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) have backed the publication of a handbook on recommendations for the diagnosis and treatment of non-small cell lung cancer. Due to the high incidence and mortality of this disease, the best scientific evidence must be constantly updated and made available for consultation by healthcare professionals. To draw up these recommendations, we called on a wide-ranging group of experts from the different specialties, who have prepared a comprehensive review, divided into 4 main sections. The first addresses disease prevention and screening, including risk factors, the role of smoking cessation, and screening programs for early diagnosis. The second section analyzes clinical presentation, imaging studies, and surgical risk, including cardiological risk and the evaluation of respiratory function. The third section addresses cytohistological confirmation and staging studies, and scrutinizes the TNM and histological classifications, non-invasive and minimally invasive sampling methods, and surgical techniques for diagnosis and staging. The fourth and final section looks at different therapeutic aspects, such as the role of surgery, chemotherapy, radiation therapy, a multidisciplinary approach according to disease stage, and other specifically targeted treatments, concluding with recommendations on the follow-up of lung cancer patients and surgical and endoscopic palliative interventions in advanced stages.


Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/therapy , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Biomarkers, Tumor/blood , Bronchoscopy , Carcinoma, Non-Small-Cell Lung/prevention & control , Chemoradiotherapy , Diagnostic Techniques, Respiratory System/standards , Early Detection of Cancer , Humans , Lung Neoplasms/prevention & control , Neoplasm Staging , Palliative Care , Pneumonectomy/standards , Positron Emission Tomography Computed Tomography , Pulmonary Medicine/organization & administration , Salvage Therapy , Smoking Cessation , Societies, Medical , Spain , Tomography, X-Ray Computed
13.
Arch. bronconeumol. (Ed. impr.) ; 52(supl.1): 2-62, mayo 2016. tab, graf
Article Es | IBECS | ID: ibc-158439
14.
Arch. bronconeumol. (Ed. impr.) ; 52(4): 204-210, abr. 2016. graf
Article Es | IBECS | ID: ibc-150700

Introducción: Benchmarking hace referencia a la comparación continuada de la eficiencia y la calidad entre productos y actividades con el objetivo fundamental de alcanzar la excelencia. Objetivo: Analizar los resultados del benchmarking realizado en 2013 con la actividad asistencial de Cirugía Torácica en el año 2012 en 17 servicios de Cirugía Torácica españoles participantes. Métodos: La fuente de información para el estudio ha sido el conjunto mínimo básico de datos de hospitalización correspondiente al año 2012. Los datos han sido proporcionados por los centros participantes, a partir de los informes de alta hospitalaria, sin intervención de los responsables de los correspondientes servicios asistenciales. Los casos objeto del estudio han sido todas las altas de hospitalización registradas en los centros participantes. Los episodios incluidos han sido los de enfermedad quirúrgica respiratoria (CDM4-Q) y los del servicio de Cirugía Torácica. La identificación de estos casos se realizó usando los códigos de la novena edición de la Clasificación Internacional de Enfermedades, Modificación Clínica. Para valorar las diferencias en gravedad y complejidad de los casos se ha utilizado la clasificación de los grupos relacionados por el diagnóstico refinados. Resultados: Los diversos parámetros generales estudiados (casuística, estancia media, complicaciones, readmisiones, mortalidad y actividad) han tenido una gran variabilidad entre los participantes. El análisis concreto de intervenciones (lobectomía, neumonectomía, resecciones atípicas y neumotórax), también han oscilado considerablemente. Conclusiones: Se observa, al igual que en ediciones previas, una considerable variabilidad entre los grupos participantes. Existen áreas de mejora evidentes: estandarización de los procesos de admisión, evitando ingresos urgentes y mejorando la estancia preoperatoria; agilización de las altas hospitalarias y mejora de los informes de alta, reflejando toda la actividad y las complicaciones habidas. Algunas unidades de Cirugía Torácica deben hacer una revisión profunda de sus procesos porque pueden tener algunos parámetros con una desviación excesiva de la norma. También deben mejorarse los procesos de codificación de diagnósticos y comorbilidades


Introduction: Benchmarking entails continuous comparison of efficacy and quality among products and activities, with the primary objective of achieving excellence. Objective: To analyze the results of benchmarking performed in 2013 on clinical practices undertaken in 2012 in 17 Spanish thoracic surgery units. Methods: Study data were obtained from the basic minimum data set for hospitalization, registered in 2012. Data from hospital discharge reports were submitted by the participating groups, but staff from the corresponding departments did not intervene in data collection. Study cases all involved hospital discharges recorded in the participating sites. Episodes included were respiratory surgery (Major Diagnostic Category 04, Surgery), and those of the thoracic surgery unit. Cases were labelled using codes from the International Classification of Diseases, 9th revision, Clinical Modification. The refined diagnosis-related groups classification was used to evaluate differences in severity and complexity of cases. Results: General parameters (number of cases, mean stay, complications, readmissions, mortality, and activity) varied widely among the participating groups. Specific interventions (lobectomy, pneumonectomy, atypical resections, and treatment of pneumothorax) also varied widely. Conclusions: As in previous editions, practices among participating groups varied considerably. Some areas for improvement emerge: admission processes need to be standardized to avoid urgent admissions and to improve pre-operative care; hospital discharges should be streamlined and discharge reports improved by including all procedures and complications. Some units have parameters which deviate excessively from the norm, and these sites need to review their processes in depth. Coding of diagnoses and comorbidities is another area where improvement is needed


Humans , Male , Female , Thoracic Surgery/instrumentation , Thoracic Surgery/methods , Thoracic Surgery/trends , Benchmarking/methods , Benchmarking/trends , Benchmarking , Efficiency, Organizational/trends , Pneumonectomy/instrumentation , Pneumonectomy/methods , Pneumonectomy , Pneumothorax , Carcinoma, Bronchogenic/surgery , Carcinoma, Bronchogenic/therapy , Spain
15.
Arch Bronconeumol ; 52(4): 204-10, 2016 Apr.
Article En, Es | MEDLINE | ID: mdl-26654629

INTRODUCTION: Benchmarking entails continuous comparison of efficacy and quality among products and activities, with the primary objective of achieving excellence. OBJECTIVE: To analyze the results of benchmarking performed in 2013 on clinical practices undertaken in 2012 in 17 Spanish thoracic surgery units. METHODS: Study data were obtained from the basic minimum data set for hospitalization, registered in 2012. Data from hospital discharge reports were submitted by the participating groups, but staff from the corresponding departments did not intervene in data collection. Study cases all involved hospital discharges recorded in the participating sites. Episodes included were respiratory surgery (Major Diagnostic Category 04, Surgery), and those of the thoracic surgery unit. Cases were labelled using codes from the International Classification of Diseases, 9th revision, Clinical Modification. The refined diagnosis-related groups classification was used to evaluate differences in severity and complexity of cases. RESULTS: General parameters (number of cases, mean stay, complications, readmissions, mortality, and activity) varied widely among the participating groups. Specific interventions (lobectomy, pneumonectomy, atypical resections, and treatment of pneumothorax) also varied widely. CONCLUSIONS: As in previous editions, practices among participating groups varied considerably. Some areas for improvement emerge: admission processes need to be standardized to avoid urgent admissions and to improve pre-operative care; hospital discharges should be streamlined and discharge reports improved by including all procedures and complications. Some units have parameters which deviate excessively from the norm, and these sites need to review their processes in depth. Coding of diagnoses and comorbidities is another area where improvement is needed.


Benchmarking , Thoracic Surgical Procedures/standards , Humans , Spain
16.
Cir. Esp. (Ed. impr.) ; 93(9): 589-593, nov. 2015. tab
Article Es | IBECS | ID: ibc-144547

INTRODUCCIÓN: La aparición de una nueva lesión pulmonar, bien un tumor metacrónico o una recidiva, en pacientes neumonectomizados plantea un reto terapéutico, en el que la cirugía en muchas ocasiones se considera contraindicada. El objetivo de nuestro estudio es valorar la morbimortalidad de la cirugía de resección pulmonar sobre pulmón único. MÉTODOS: Revisamos a todos los pacientes a los que se les realizó una neumonectomía y presentaron una nueva lesión en el pulmón remanente entre 1994 y 2012. RESULTADOS: La serie consta de 12 pacientes (10 varones y 2 mujeres) con una edad media de 71 años (54-81 años). El FEV1 medio fue de 1.470 ml (54,2%) y la CVF de 2.153 ml (61,5%). Tras una mediana de 34,5 meses se les intervino de una segunda lesión en el pulmón contralateral, realizándose en todos los casos resecciones pulmonares atípicas. La anatomía patológica mostró metástasis de tumor primario pulmonar en 2 pacientes; tumor metacrónico, en 6 pacientes; metástasis de carcinoma de origen extratorácico, en 3 pacientes y nódulo benigno en un paciente. Se registraron complicaciones en 4 pacientes (33,4%): arritmia cardíaca en 2 pacientes e insuficiencia respiratoria en otros 2 pacientes. No hubo ningún fallecimiento postoperatorio. CONCLUSIÓN: La resección pulmonar sobre pulmón único es un procedimiento seguro con una aceptable morbimortalidad, en la que es de gran importancia una meticulosa selección de los pacientes


BACKGROUND: After pneumonectomy, the development of a new lung cancer or a recurrence in the residual lung is a challenge. Surgery often is considered contraindicated. The goal of our study is to assess the morbidity and mortality of lung resection on a single lung. METHODS: All patients who underwent lung resection after pneumonectomy from January 1996 through December 2012 were reviewed. RESULTS: There were 12 patients (10 men and 2 women). Mean age was 71 years (range, 54-81 years). Mean preoperative FEV1 was 1470 ml (52%) and preoperative FVC 2153 ml (61,5%). Subsequent pulmonary resection was performed after a median follow-up of 34,5 months. Wedge resection was performed in all patients. Diagnosis was pulmonary mestastatic lung cancer in 2 patients, metachronous lung cancer in 6, metastatic extrathoracic cancer in 3 and benign nodule in one. Complications occurred in 4 patients (33,4%) while operative mortality was nil. CONCLUSIONS: Lung resection on a single lung is a safe procedure associated with acceptable morbidity and mortality. Careful patient selection is very important


Aged, 80 and over , Aged , Humans , Middle Aged , Pneumonectomy/methods , Lung Neoplasms/surgery , Treatment Outcome , Neoplasm Recurrence, Local/surgery , Retrospective Studies
17.
Cir Esp ; 93(9): 589-93, 2015 Nov.
Article En, Es | MEDLINE | ID: mdl-26277461

BACKGROUND: After pneumonectomy, the development of a new lung cancer or a recurrence in the residual lung is a challenge. Surgery often is considered contraindicated. The goal of our study is to assess the morbidity and mortality of lung resection on a single lung. METHODS: All patients who underwent lung resection after pneumonectomy from January 1996 through December 2012 were reviewed. RESULTS: There were 12 patients (10 men and 2 women). Mean age was 71 years (range, 54-81 years). Mean preoperative FEV1 was 1,470 ml (52%) and preoperative FVC 2,153 ml (61,5%). Subsequent pulmonary resection was performed after a median follow-up of 34,5 months. Wedge resection was performed in all patients. Diagnosis was pulmonary mestastatic lung cancer in 2 patients, metachronous lung cancer in 6, metastatic extrathoracic cancer in 3 and benign nodule in one. Complications occurred in 4 patients (33,4%) while operative mortality was nil. CONCLUSIONS: Lung resection on a single lung is a safe procedure associated with acceptable morbidity and mortality. Careful patient selection is very important.


Pneumonectomy , Aged , Aged, 80 and over , Female , Humans , Lung Neoplasms , Male , Middle Aged , Neoplasm Recurrence, Local/etiology , Neoplasms, Second Primary/etiology , Patient Selection , Pneumonectomy/adverse effects , Postoperative Complications/etiology , Retrospective Studies
18.
Arch. bronconeumol. (Ed. impr.) ; 49(11): 491-493, nov. 2013. ilus, tab
Article Es | IBECS | ID: ibc-129139

El cordoma condroide de localización vertebral torácica es un tipo de tumor que constituye una auténtica rareza. La incidencia anual del cordoma condroide se cifra en 0,1/100.000 habitantes, y la afectación torácica se aprecia en el 2 al 5% de los casos. Su diagnóstico definitivo se ve complicado por su semejanza con otros tumores como los condrosarcomas, por lo que es preciso acudir al estudio inmunohistoquímico.Su capacidad de recidiva y la tendencia a la malignización a pesar de su naturaleza de lento crecimiento provocan que su tratamiento, predominantemente quirúrgico, sea de una complejidad nada desdeñable. Su comportamiento evolutivo tan agresivo está siendo motivo de estudio a nivel molecular y genético para la elaboración de nuevas terapias oncológicas médicas con el fin de complementar la cirugía y la radioterapia, cuando estas sean aplicables. Se presenta un caso de localización torácica vertebral e intrapleural, así como el tratamiento practicado (AU)


Chondroid chordoma is an extremely rare tumour with an annual incidence of around 0.1 cases per 100 000 population. Involvement of the thoracic vertebrae may be present in 2%–5% of cases. Definitive diagnosis usually requires a suitable distinction between this and other mesenchymal tumours such as chondrosarcomas, so immunohistochemical analysis is virtually mandatory. In spite of its slow-growing nature, chondroid chordoma tends to relapse, and it may eventually become malignant, often jeopardising the patient's prognosis. Although surgery remains the main therapeutic approach, research into the molecular and genetic aspects of this tumour is ongoing. These new advances are likely to improve future oncology therapies by complementing surgery and radiotherapy, changing the currently poor prognosis.We report the case of a patient with a chondroid chordoma involving the thoracic vertebrae and pleural cavity, and the treatment performed (AU)


Humans , Chordoma/pathology , Spinal Neoplasms/pathology , Thoracic Neoplasms/pathology , Pleural Neoplasms/pathology
19.
Arch Bronconeumol ; 49(11): 491-3, 2013 Nov.
Article En, Es | MEDLINE | ID: mdl-23791243

Chondroid chordoma is an extremely rare tumour with an annual incidence of around 0.1 cases per 100,000population. Involvement of the thoracic vertebrae may be present in 2-5% of cases. Definitive diagnosis usually requires a suitable distinction between this and other mesenchymal tumours such as chondrosarcomas, so immunohistochemical analysis is virtually mandatory. In spite of its slow-growing nature, chondroid chordoma tends to relapse, and it may eventually become malignant, often jeopardising the patient's prognosis. Although surgery remains the main therapeutic approach, research into the molecular and genetic aspects of this tumour is ongoing. These new advances are likely to improve future oncology therapies by complementing surgery and radiotherapy, changing the currently poor prognosis. We report the case of a patient with a chondroid chordoma involving the thoracic vertebrae and pleural cavity, and the treatment performed.


Chordoma/diagnosis , Pleural Cavity/pathology , Thoracic Neoplasms/diagnosis , Thoracic Vertebrae/pathology , Antineoplastic Agents/therapeutic use , Chordoma/diagnostic imaging , Chordoma/pathology , Chordoma/secondary , Chordoma/therapy , Combined Modality Therapy , Curettage , Diagnostic Errors , Diaphragm/pathology , Echinococcosis/diagnosis , ErbB Receptors/antagonists & inhibitors , Humans , Laminectomy , Magnetic Resonance Imaging , Male , Middle Aged , Muscle Neoplasms/secondary , Neoplasm Invasiveness , Neoplasm Proteins/antagonists & inhibitors , Pleural Cavity/diagnostic imaging , Pleural Neoplasms/secondary , Prostheses and Implants , Protein Kinase Inhibitors/therapeutic use , Radiotherapy, Adjuvant , Remission Induction , Sarcoma/diagnosis , Thoracic Neoplasms/diagnostic imaging , Thoracic Neoplasms/pathology , Thoracic Neoplasms/therapy , Thoracic Vertebrae/diagnostic imaging , Tomography, X-Ray Computed
20.
Arch. bronconeumol. (Ed. impr.) ; 49(3): 122-125, mar. 2013. ilus
Article Es | IBECS | ID: ibc-110067

Los carcinoides tímicos son una entidad poco frecuente que puede asociarse a enfermedades endocrinológicas como el síndrome de Cushing o el síndrome de neoplasia endocrina múltiple tipo I (MEN1). Suponen el 4% de los tumores del mediastino anterior y se caracterizan por tener un comportamiento muy agresivo. Presentamos el caso de un paciente diagnosticado de síndrome MEN1 a quien durante el seguimiento de su enfermedad se detectó una imagen torácica compatible con carcinoide tímico. Tras intervenirle quirúrgicamente mediante timectomía ampliada a grasa peritímica, se confirmó el diagnóstico clínico. A los 14 meses de seguimiento se halló en las pruebas de imagen una lesión sospechosa de recidiva local, motivo por el que fue reintervenido. El informe anatomopatológico de dicha intervención fue de fibrosis rádica. Así mismo, presentamos una revisión del manejo diagnóstico y terapéutico actual en pacientes con síndrome MEN1 diagnosticados de carcinoide tímico(AU)


Thymic carcinoids are a rare entity that may be associated with endocrine diseases like Cushing's syndrome or multiple endocrine neoplasia syndrome type I (MEN1). These tumors represent 4% of anterior mediastinal tumors and are characterized by their very aggressive behavior. We present the case of a patient with a previous MEN 1 diagnosis in whom, during the follow up of his disease, a thoracic image compatible with thymic carcinoid was detected. After an extended thymectomy that included peri-thymic fat resection, the clinical diagnosis was confirmed. A follow-up examination 14 months later revealed a suspicious lesion that suggested local recurrence, therefore the patient was reoperated on. The pathology report of this surgery indicated post-radiation fibrosis. Likewise, we present a review of the current diagnostic and therapeutic management of patients with MEN1 syndrome who are diagnosed with thymic carcinoid(AU)


Humans , Thymoma/complications , Thymus Neoplasms/complications , Multiple Endocrine Neoplasia/complications , Thymectomy , Risk Factors
...